Mereo Biopharma Group PLC
NASDAQ:MREO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mereo Biopharma Group PLC
Operating Income
Mereo Biopharma Group PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Operating Income
-£40.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£45.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Operating Income
-$179m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£83m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Operating Income
-£32.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-9%
|
|
|
Niox Group PLC
LSE:NIOX
|
Operating Income
£10.7m
|
CAGR 3-Years
81%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mereo Biopharma Group PLC
Glance View
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).
See Also
What is Mereo Biopharma Group PLC's Operating Income?
Operating Income
-40.1m
GBP
Based on the financial report for Dec 31, 2025, Mereo Biopharma Group PLC's Operating Income amounts to -40.1m GBP.
What is Mereo Biopharma Group PLC's Operating Income growth rate?
Operating Income CAGR 5Y
4%
Over the last year, the Operating Income growth was 15%. The average annual Operating Income growth rates for Mereo Biopharma Group PLC have been 9% over the past three years , 4% over the past five years .
